Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Wacker adds research services for nucleic-acid therapeutics

Wacker is expanding contract research to include RNA and plasmid construct design alongside its existing RNA, pDNA and LNP formulation activities. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Industry

GEN reports: Wacker is expanding contract research to include RNA and plasmid construct design alongside its existing RNA, pDNA and LNP formulation activities.

The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance. Consult the linked GEN report for the source organisation’s full announcement.

Lipid Nanoparticles & RNA Therapeutics

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.

Prefer to talk it through? Book a 30-minute discovery call

Wacker adds research services for nucleic-acid therapeutics | Brilliant Blue Biosciences